Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 28
Adv Rheumatol ; 62: 3, 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1360070


Abstract Objective: To provide guidelines on the coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated rheumatic diseases (IMRD) to rheumatologists considering specific scenarios of the daily practice based on the shared-making decision (SMD) process. Methods: A task force was constituted by 24 rheumatologists (panel members), with clinical and research expertise in immunizations and infectious diseases in immunocompromised patients, endorsed by the Brazilian Society of Rheumatology (BSR), to develop guidelines for COVID-19 vaccination in patients with IMRD. A consensus was built through the Delphi method and involved four rounds of anonymous voting, where five options were used to determine the level of agreement (LOA), based on the Likert Scale: (1) strongly disagree; (2) disagree, (3) neither agree nor disagree (neutral); (4) agree; and (5) strongly agree. Nineteen questions were addressed and discussed via teleconference to formulate the answers. In order to identify the relevant data on COVID-19 vaccines, a search with standardized descriptors and synonyms was performed on September 10th, 2021, of the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials,, and LILACS to identify studies of interest. We used the Newcastle-Ottawa Scale to assess the quality of nonrandomized studies. Results: All the nineteen questions-answers (Q&A) were approved by the BSR Task Force with more than 80% of panelists voting options 4—agree—and 5—strongly agree—, and a consensus was reached. These Guidelines were focused in SMD on the most appropriate timing for IMRD patients to get vaccinated to reach the adequate covid-19 vaccination response. Conclusion: These guidelines were developed by a BSR Task Force with a high LOA among panelists, based on the literature review of published studies and expert opinion for COVID-19 vaccination in IMRD patients. Noteworthy, in the pandemic period, up to the time of the review and the consensus process for this document, high-quality evidence was scarce. Thus, it is not a substitute for clinical judgment.

Int. j. cardiovasc. sci. (Impr.) ; 32(1): 10-18, jan.-fev. 2019. tab, graf
Article in Portuguese | LILACS | ID: biblio-981520


Background: Cardiovascular diseases are a major cause of morbidity and mortality today. Despite its wide distribution, it presents particularly prevalent in certain groups of individuals, particularly when exposed to a higher degree of inflammation, giving increased cardiovascular risk. Rheumatic diseases expose their holders to this increased cardiovascular risk condition; however only recently have been associated with spondyloarthritis, particularly ankylosing spondylitis (AS). For being a classically autoimmune disease related to HLA histocompatibility system, AS may present phenotypic variations in different ethnic groups with possible diverse cardiovascular consequences. Objectives: To estimate the prevalence of cardiovascular disease (CVD) and the cardiovascular risk profile, correlating the time since diagnosis and activity of ankylosing spondylitis (AS) in patients from the rheumatology outpatient clinic of the UFMS-affiliated hospital. Methods: Of 55 patients with AS, 42 were selected consecutively and compared to a control group (CG) in a cross-sectional study. Patients with diabetes, indigenous background and pregnant women were excluded. Quantitative variables were assessed by use of Student t test, while qualitative variables, by chi-square test. The patients underwent electrocardiography, echocardiography and carotid Doppler examination, measurement of serum lipid levels and inflammatory markers, and were stratified according to global cardiovascular risk. The AS activity and impairment were evaluated by use of the BASMI, BASDAI, BASFI and ASDAS. Results: Mean age, 42.87 ± 12.37 years; time since AS diagnosis, 10.76 ± 8.74 years. There was no difference in cardiovascular risk stratification between the groups, most of the patients being at high or moderate risk (AS: 64.3%, and CG: 52%, p = 0.134). The prevalence of manifest CVD (2%) showed no difference between the groups, except for right bundle-branch block (AS: 14%, and CG: 2%, p = 0.027). The prevalence of subclinical CVD showed no difference between the groups, except for higher carotid medial-intimal thickness (CIMT) in the AS group (AS: 1.82 ± 2.63, and CG: 0.67 ± 0.16, p = 0.018). There was no correlation between AS activity or inflammatory markers and CVD, but with time since AS diagnosis and CIMT (p = 0.039, r = 0.328). Conclusions: Prevalence of CVD and risk factors was similar in the groups. Subclinical atherosclerosis degree was higher in the AS group, related to the time since diagnosis, but was independent of the cardiovascular risk factors or inflammation. Most patients with AS are at high cardiovascular risk

Humans , Male , Female , Adult , Outpatients , Spondylitis, Ankylosing/complications , Spondylitis, Ankylosing/diagnosis , Cardiovascular Diseases , Rheumatic Diseases , Echocardiography/methods , Carotid Arteries , Body Mass Index , Prevalence , Statistical Analysis , Risk Factors , Metabolic Syndrome , Diabetes Mellitus , Electrocardiography/methods , Atherosclerosis , Hypertension , Cholesterol, HDL , Cholesterol, LDL
Adv Rheumatol ; 59: 17, 2019. tab, graf
Article in English | LILACS | ID: biblio-1088607


Abstract Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the safety of YFV in patients with CIMID, considering the immunosuppression degree conferred by the treatment used. It was not possible to establish recommendations on the effectiveness of YFV in these patients as there is no consistent evidence to support these recommendations. Conclusion: This paper approaches a real need, assessed by clinicians and patient care groups, to address specific questions on the management of YFV in patients with CIMID living or traveling to YF endemic areas, involving specialists from many areas together with patients, and might have global applicability, contributing to and supporting vaccination practices. We recommended a shared decision-making approach on taking or not the YFV.

Humans , Yellow Fever/prevention & control , Chronic Disease , Yellow Fever Vaccine/administration & dosage , Brazil/epidemiology , Efficacy/standards , Treatment Outcome
Rev. bras. reumatol ; 57(2): 107-114, Mar.-Apr. 2017. tab
Article in English | LILACS | ID: biblio-844224


Abstract Introduction: Systemic sclerosis is an autoimmune disease which shows extreme heterogeneity in its clinical presentation and that follows a variable and unpredictable course. Although some discrepancies in the incidence and prevalence rates between geographical regions may reflect methodological differences in the definition and verification of cases, they may also reflect true local differences. Objectives: To determine the prevalence and incidence of systemic sclerosis in the city of Campo Grande, state capital of Mato Grosso do Sul (MS), Brazil, during the period from January to December 2014. Methods: All health care services of the city of Campo Grande – MS with attending in the specialty of Rheumatology were invited to participate in the study through a standardized form of clinical and socio-demographic assessment. Physicians of any specialty could report a suspected case of systemic sclerosis, but necessarily the definitive diagnosis should be established by a rheumatologist, in order to warrant the standardization of diagnostic criteria and exclusion of other diseases resembling systemic sclerosis. At the end of the study, 15 rheumatologists reported that they attended patients with systemic sclerosis and sent the completed forms containing epidemiological data of patients. Results: The incidence rate of systemic sclerosis in Campo Grande for the year 2014 was 11.9 per million inhabitants and the prevalence rate was 105.6 per million inhabitants. Systemic sclerosis patients were mostly women, white, with a mean age of 50.58 years, showing the limited form of the disease with a mean duration of the disease of 8.19 years. Regarding laboratory tests, 94.4% were positive for antinuclear antibody, 41.6% for anti-centromere antibody and 19.1% for anti-Scl70; anti-RNA Polymerase III was performed in 37 patients, with 16.2% positive. Conclusions: The city of Campo Grande, the state capital of MS, presented a lower incidence/prevalence of systemic sclerosis in comparison with those numbers found in US studies and close to European studies’ data.

Resumo Introdução: A esclerose sistêmica (ES) é uma enfermidade autoimune, extremamente heterogênea na sua apresentação clínica e segue um curso variável e imprevisível. Embora algumas discrepâncias nas taxas de incidência e prevalência entre regiões possam refletir as diferenças metodológicas na definição e verificação dos casos, elas também podem refletir as verdadeiras diferenças locais. Objetivos: Conhecer a prevalência e incidência da ES na cidade de Campo Grande, capital do Estado de Mato Grosso do Sul (MS), Brasil, de janeiro a dezembro de 2014. Métodos: Todos os serviços de saúde de Campo Grande (MS) que tinham atendimentos na especialidade de reumatologia foram convidados a participar do estudo por meio de ficha padronizada de avaliação clínica e sociodemográfica. Médicos de qualquer especialidade poderiam reportar um caso suspeito de ES, mas obrigatoriamente o diagnóstico definitivo deveria ser feito por um reumatologista, para garantir a padronização dos critérios diagnósticos e excluir outras doenças que se assemelham à ES. No fim do estudo 15 reumatologistas relataram ter atendido pacientes com diagnóstico de ES e enviaram os formulários preenchidos com os dados epidemiológicos dos pacientes. Resultados: A taxa de incidência de ES em Campo Grande em 2014 foi de 11,9 por milhão/habitantes e a de prevalência foi de 105,6 por milhão/habitantes. Os pacientes com ES eram principalmente mulheres, da cor branca, média de 50,58 anos, forma limitada da doença e tempo de evolução médio da doença de 8,19 anos. Em relação aos exames laboratoriais, observou-se a positividade de 94,4% para o ANA, 41,6% para ACA e 19,1% para anti-Scl70, o anticorpo anti-POL3 foi feito em apenas 37 pacientes, com positividade de 16,2%. Conclusões: A capital do Estado de Mato Grosso do Sul, Campo Grande, apresentou dados de incidência e prevalência de ES inferiores aos encontrados em estudos americanos e próximos aos dados observados em estudos europeus.

Humans , Male , Female , Adult , Aged , Scleroderma, Systemic/epidemiology , Scleroderma, Systemic/therapy , Brazil/epidemiology , Incidence , Prevalence , Prospective Studies , Sex Distribution , Diagnosis, Differential , Rheumatologists/statistics & numerical data , Middle Aged
Rev. bras. reumatol ; 57(supl.2): s421-s437, 2017. tab
Article in English | LILACS | ID: biblio-899486


Abstract Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.

Resumo A febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias. Até 2013, as Américas haviam registrado apenas casos importados quando, em outubro desse mesmo ano, foram notificados os primeiros casos na Ilha de Saint Martin, no Caribe. No Brasil, os primeiros relatos autóctones foram confirmados em setembro de 2014 e até a semana epidemiológica 37 de 2016 já haviam sido registrados 236.287 casos prováveis de infecção pelo chikungunya vírus (CHIKV), 116.523 confirmados sorologicamente. As mudanças ambientais causadas pelo homem, o crescimento urbano desordenado e o número cada vez maior de viagens internacionais têm sido apontados como os fatores responsáveis pela reemergência de epidemias em grande escala. Caracterizada clinicamente por febre e dor articular na fase aguda, em cerca de metade dos casos existe evolução para a fase crônica (além de três meses), com dor persistente e incapacitante. O objetivo deste trabalho foi elaborar recomendações para diagnóstico e tratamento da febre chikungunya no Brasil. Para isso, foi feita revisão da literatura nas bases de dados Medline, SciELO e PubMed, para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Foram geradas 25 recomendações, divididas em três grupos temáticos: (1) diagnóstico clínico, laboratorial e por imagem; (2) situações especiais e (3) tratamento. Na primeira parte estão os dois primeiros temas e o tratamento na segunda.

Humans , Male , Female , Pregnancy , Chikungunya Fever/diagnosis , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/therapy , Rheumatology , Societies, Medical , Brazil , Delphi Technique , Consensus , Chikungunya Fever/physiopathology , Chikungunya Fever/therapy
Rev. bras. reumatol ; 57(supl.2): s438-s451, 2017. tab, graf
Article in English | LILACS | ID: biblio-899488


Abstract Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used. The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia - SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.

Resumo A febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias, visto que metade dos casos evolui com artrite crônica, persistente e incapacitante. Os dados na literatura sobre terapêuticas específicas nas diversas fases da artropatia ocasionada pela infecção pelo vírus chikungunya (CHIKV) são limitados, não existem estudos randomizados de qualidade que avaliem a eficácia das diferentes terapias. Há algumas poucas publicações sobre o tratamento das manifestações musculoesqueléticas da febre chikungunya, porém com importantes limitações metodológicas. Os dados atualmente disponíveis não permitem conclusões favoráveis ou contrárias a terapêuticas específicas, bem como uma adequada avaliação quanto à superioridade entre as diferentes medicações empregadas. O objetivo deste trabalho foi elaborar recomendações para o tratamento da febre chikungunya no Brasil. Foi feita uma revisão da literatura com seleção de artigos baseados em evidência, nas bases de dados Medline, SciELO, PubMed e Embase e de resumos de anais de congressos, além da opinião dos especialistas para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Este artigo refere-se à parte 2 das Recomendações da Sociedade Brasileira de Reumatologia para Diagnóstico e Tratamento da Febre Chikungunya, que trata especificamente do tratamento.

Humans , Chikungunya Fever/drug therapy , Rheumatology , Societies, Medical , Brazil , Delphi Technique , Physical Therapy Modalities , Disease Progression , Consensus , Chikungunya Fever/diagnosis , Chikungunya Fever/rehabilitation
Rev. bras. reumatol ; 56(4): 287-298, July-Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-792760


ABSTRACT Introduction: Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue characterized by the triad of vascular injury, autoimmunity (cellular and humoral) and tissue fibrosis. It is estimated that musculoskeletal pain is a common complaint of patients with SSc, ranging from 40 to 80%, and mainly in patients with early diffuse disease. Arthritis, clinically observed, may be a feature seen in the presentation of SSc, often leading to early diagnostic errors with rheumatoid arthritis (RA). In the course of the disease, arthritis is observed in 24–97% of patients with SSc. Objectives: To correlate the occurrence or nonoccurrence of arthritis in patients with SSc of the Midwest region of Brazil with possible distinct clinical and laboratory manifestations observed in three groups of patients. To report the frequency of true association between systemic sclerosis and rheumatoid arthritis in patients with clinically and radiologically observed synovitis. Methods: Sixty-one SSc patients were subsequently assessed every 3 months within 1 year, in order to clinically observe the occurrence of synovitis and its patterns of progression. Patients were divided into 3 groups: 41 patients with SSc without arthritis, 16 SSc patients with arthritis and 4 patients with overlap of SSc and RA. All patients underwent a radiological examination of the hands at the end of the study. Results: Among all patients evaluated, we found a female predominance (98.7%), mean age of 50.94 years, white color (49.2%), limited form of the disease (47.6%), time of diagnosis between 5 and 10 years (47.6%) and duration of the disease of 8.30 years. Among all patients, 14 (22.9%) had positive rheumatoid factor (RF), while among those with positive RF, only 10 patients had arthritis during one-year follow-up. The antibody anticitrulline (anti-CCP) test was performed in 24 patients, being positive in 4 of them (16.7%), with positivity being observed only in patients with SSc/RA overlap. Comparing the clinical manifestations among the groups of patients, there was a higher incidence of gastritis and cardiac valvulopathy in patients with SSc and arthritis, but not in the others. In the group of patients with SSc/RA overlap and in patients with SSc and arthritis a significant reduction in quality of life was observed, measured by HAQ index, especially in patients with arthritis present during clinical evaluation. We found radiographic changes in 42.6% of patients with SSc. However, in patients with synovitis, radiological changes consistent with rheumatoid arthritis were found in 50% of patients. Conclusions: While the frequency of clinical arthritis observed in patients with systemic sclerosis was 32.8%, the true overlap between of SSc and RA was 6.6% in this study. We also observed the frequency of positive anti-CCP in 20% of patients with arthritis versus no patients with SSc without arthritis.

RESUMO Introdução: A esclerose sistêmica (ES) é uma enfermidade do tecido conjuntivo de caráter autoimune caracterizada pela tríade de injúria vascular, autoimunidade (celular e humoral) e fibrose tecidual. Estima-se que a dor musculoesquelética seja uma queixa frequente dos pacientes com ES, que oscila entre 40% e 80%, e principalmente em pacientes com doença difusa precoce. A artrite, clinicamente observada, pode ser uma característica observada na apresentação da ES, frequentemente leva a erros diagnósticos iniciais com artrite reumatoide (AR). No curso da enfermidade, a artrite é observada em 24% a 97% dos pacientes com ES. Objetivos: Correlacionar a ocorrência ou não de artrite em pacientes com ES da região Centro-Oeste do Brasil com possíveis manifestações clínicas e laboratoriais distintas observadas em três grupos de pacientes. Relatar a frequência de verdadeira associação entre esclerose sistêmica e artrite reumatoide em pacientes com sinovite clínica e radiologicamente observada. Métodos: Foram avaliados 61 pacientes portadores de ES subsequentemente a cada três meses durante um ano, para fins de se constatar clinicamente a ocorrência de sinovite e padrões de evolução. Os pacientes foram divididos em três grupos: 41 com ES sem artrite, 16 com ES com artrite e quatro com sobreposição entre ES e AR. Todos os pacientes foram submetidos a exame radiológicos das mãos no fim do estudo. Resultados: Dentre todos os pacientes avaliados, encontrou-se predomínio feminino (98,7%), idade média de 50,94 anos, cor branca (49,2%), forma limitada da doença (47,6%), tempo de diagnóstico entre cinco e 10 anos (47,6%) e tempo de evolução da doença de 8,30 anos. Entre todos os pacientes, 14 (22,9%) apresentavam fator reumatoide (FR) positivo, embora entre aqueles com FR positivo apenas 10 apresentaram artrite durante o seguimento de um ano. O anticorpo anticitrulina (anti- CCP) foi feito em 24 pacientes, com positividade em quatro deles (16,7%), observada somente nos pacientes com sobreposição ES/AR. Na comparação das manifestações clínicas entre os grupos de pacientes, observou-se a maior ocorrência de gastrite e valvulopatia cardíaca em pacientes com ES e artrite, mas não nos demais grupos. No grupo de pacientes com overlap ES/AR e nos pacientes com ES e artrite observou-se redução importante de qualidade de vida, medida pelo índice HAQ, sobretudo nos pacientes com artrite presente no momento da avaliação clínica. Encontramos alterações radiográficas em 42,6% dos pacientes com ES. Contudo, nos pacientes com sinovite, encontraram-se alterações radiológicas compatíveis com artrite reumatoide em 50%. Conclusões: Enquanto a frequência de artrite clínica observada em pacientes com esclerose sistêmica foi de 32,8%, a verdadeira sobreposição entre ES e AR foi de 6,6% neste estudo. Observou-se ainda a frequência de anti-CCP positivo em 20% dos pacientes com artrite contra nenhum paciente com ES sem artrite.

Humans , Female , Arthritis, Rheumatoid/complications , Scleroderma, Systemic/complications , Anti-Citrullinated Protein Antibodies/blood , Peptides, Cyclic/blood , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/blood , Quality of Life , Scleroderma, Systemic/immunology , Scleroderma, Systemic/blood , Autoantibodies/blood , Brazil , Comorbidity
Rev. bras. reumatol ; 56(4): 314-322, July-Aug. 2016. tab
Article in English | LILACS | ID: lil-792763


ABSTRACT Introduction: Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology, characterized by a triad of vascular injury, autoimmunity and tissue fibrosis. It is known that a positive family history is the greatest risk factor already identified for the development of SSc in a given individual. Preliminary observation of a high prevalence of polyautoimmunity and of familial autoimmunity in SSc patients support the idea that different autoimmune phenotypes may share common susceptibility variants. Objectives: To describe the frequency of familial autoimmunity and polyautoimmunity in 60 SSc patients in the Midwest region of Brazil, as well as to report the main autoimmune diseases observed in this association of comorbidities. Methods: A cross-sectional study with recruitment of 60 consecutive patients selected at the Rheumatology Department, University Hospital, Medicine School, Federal University of Mato Grosso do Sul (FMUFMS), as well as interviews of their relatives during the period from February 2013 to March 2014. Results: A frequency of 43.3% of polyautoimmunity and of 51.7% of familial autoimmunity in SSc patients was found. Patients with the presence of polyautoimmunity and familial autoimmunity presented primarily the diffuse form of SSc, but this indicator did not reach statistical significance. The autoimmune diseases most frequently observed in polyautoimmunity patients were: Hashimoto's thyroiditis (53.8%), Sjögren's syndrome (38.5%), and inflammatory myopathy (11.5%). The main autoimmune diseases observed in SSc patients' relatives were: Hashimoto's thyroiditis (32.3%), rheumatoid arthritis (22.6%), and SLE (22.6%). The presence of more than one autoimmune disease in SSc patients did not correlate with disease severity or activity. Conclusions: From the high prevalence of coexisting autoimmune diseases found in SSc patients, we stress the importance of the concept of shared autoimmunity, in order to promote a continued vigilance and promptly diagnose other possible autoimmune disease in patients, or in their kin.

RESUMO Introdução: A esclerose sistêmica (ES) é uma enfermidade do tecido conjuntivo de etiologia desconhecida, caracterizada pela tríade de injúria vascular, autoimunidade e fibrose tecidual. Sabe-se que uma história familiar positiva representa o maior fator de risco já identificado para o desenvolvimento da ES em um determinado indivíduo. Observação prévia de alta prevalência de poliautoimunidade e de autoimunidade familiar em pacientes com ES reforça a ideia de que fenótipos autoimunes distintos podem dividir variantes comuns de susceptibilidade. Objetivos: Descrever a frequência de autoimunidade familiar e de poliautoimunidade em 60 pacientes com ES da região Centro-Oeste do Brasil, bem como relatar as principais doenças autoimunes observadas nessa associação de comorbidades. Métodos: Estudo transversal com recrutamento de 60 pacientes consecutivos, selecionados no Serviço de Reumatologia do Hospital Universitário da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul (FMUFMS), bem como entrevista de seus parentes, de fevereiro de 2013 a março de 2014. Resultados: Foi encontrada uma frequência de 43,3% de poliautoimunidade e de 51,7% de autoimunidade familiar nos pacientes com ES. Os pacientes com presença de poliautoimunidade e de autoimunidade familiar eram principalmente da forma difusa de ES, porém esse índice não atingiu significância estatística. As doenças autoimunes mais comumente observadas nos pacientes com poliautoimunidade foram: tireoidite de Hashimoto (53,8%), síndrome de Sjögren (38,5%) e miopatia inflamatória (11,5%). As principais doenças autoimunes observadas nos parentes dos pacientes com ES foram: tireoidite de Hashimoto (32,3%), artrite reumatoide (22,6%) e LES (22,6%). A presença de mais de uma enfermidade autoimune em pacientes com ES não se correlacionou com maior gravidade ou atividade da doença. Conclusões: A partir da alta prevalência encontrada de doenças autoimunes coexistentes em pacientes com ES, salientamos a importância do conceito de autoimunidade compartilhada, de forma a promover uma vigilância constante e diagnosticar prontamente uma possível outra doença autoimune nos pacientes ou em seus parentes.

Scleroderma, Systemic/immunology , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/epidemiology , Scleroderma, Systemic/complications , Scleroderma, Systemic/epidemiology , Autoantibodies , Thyroiditis, Autoimmune/complications , Thyroiditis, Autoimmune/immunology , Thyroiditis, Autoimmune/epidemiology , Brazil/epidemiology , Sjogren's Syndrome/complications , Sjogren's Syndrome/immunology , Sjogren's Syndrome/epidemiology , Autoimmunity , Cross-Sectional Studies , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/epidemiology
Rev. bras. ortop ; 51(4): 424-430, July-Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-792740


ABSTRACT OBJECTIVE: Sciatic pain secondary to lumbar disc herniation is a complex condition that is often highly limiting. The causes of pain in disc herniation are multifactorial. Two physiopathological mechanisms are involved in discogenic pain: mechanical deformation of nerve roots and a biochemical inflammatory component resulting from contact between the intervertebral disc and neural tissue, by way of the nucleus pulposus. The aim of this study was to evaluate the efficacy and safety of epidural blockade as therapy for bulging lumbar disc herniation. METHODS: A clinical study was conducted based on a retrospective and prospective survey. The blockade consisted of interlaminar puncture and bolus drug delivery. The number of procedures varied according to the clinical response, as determined through weekly evaluations and then 30, 90, and 180 days after the final session. A total of 124 patients who received one to five blockades were evaluated. RESULTS: The success rate (defining success as a reduction in sciatic pain of at least 80%) was 75.8%. CONCLUSION: The results demonstrated the therapeutic action of epidural blockade over the short term, i.e. in cases of acute pain, thus showing that intense and excruciating sciatic pain can be relieved through this technique. Because of the multifactorial genesis of sciatica and the difficulties encountered by healthcare professionals in treating this condition, epidural blockade can become part of therapeutic arsenal available. This procedure is situated between conservative treatment with an eminently clinical focus and surgical approaches.

RESUMO OBJETIVO: A dor ciática secundária a hérnia discal lombar é condição complexa e, muitas vezes, intensamente limitante. As causas de dor na herniação discal são multifatoriais. Na dor discogênica há envolvimento de dois mecanismos fisiopatológicos: a deformação mecânica das raízes nervosas e o componente bioquímico inflamatório, que resulta do contato do disco intervertebral, através do núcleo pulposo, com o tecido neural. O objetivo desta investigação foi verificar a eficácia e a segurança do bloqueio epidural como terapêutica em hérnias discais lombares protrusas. MÉTODOS: Empreendeu-se um ensaio clínico com base em levantamento retrospectivo e prospectivo. O bloqueio foi feito por punção interlaminar com administração de fármacos em bolo. O número de procedimentos variou conforme a evolução clínica, com avaliações semanais e, finalmente, aos 30, 90 e 180 dias da última sessão. Foram avaliados 124 pacientes, que receberam de um a cinco bloqueios. RESULTADOS: A taxa de sucesso (considerado como redução de no mínimo 80% na dor ciática) foi de 75,8%. CONCLUSÃO: Os resultados revelaram a ação terapêutica do bloqueio epidural em curto prazo - ou seja, na dor aguda - e demonstraram que a dor ciática intensa e excruciante pode ser aliviada com essa técnica. A gênese multifatorial da ciatalgia e as dificuldades encontradas pelos profissionais em seu tratamento permitem que o bloqueio epidural integre o arsenal terapêutico disponível. O procedimento insere-se entre o tratamento conservador, eminentemente clínico, e o cirúrgico.

Humans , Male , Female , Adult , Middle Aged , Aged , Intervertebral Disc Displacement , Low Back Pain , Nerve Block
Rev. argent. reumatol ; 27(4): 20-27, 2016. tab
Article in English | LILACS | ID: biblio-958069


Introduction: Several autoimmune diseases can be accompanied by dysfunction of the salivary glands, regardless of the presence or absence of association with Sjögren's syndrome (SS). A recent study by Maeshima and colleagues found salivary hyposecretion in 58.3% of patients with various connective tissue diseases, particularly systemic sclerosis (SSc). Objective: To determine the prevalence of SS and Sicca symptoms in patients with SSc. Assess whether the presence of SS in patients with SSc causes worsening of the disease. Methods: 69 SSc patients periodically monitored in the rheumatology clinic at NHU/UFMS composed the study. All patients were questioned about sicca symptoms and clinical features. We evaluated the RF levels, ANA, anti-Ro/La. Results and discussion: 69 SSc patients were enrolled in the study, with average age of 51.2 years, 98.3% females and 50% caucasian. Sicca symptoms were present in 48 patients (69.5%) with SSc; 43/69 patients (62.3%) with dry mouth and 46/69 patients (66.7%) with dry eye. Sicca symptoms were observed in patients with limited and diffuse form of the disease. The antinuclear antibody positivity was 95% and the rheumatoid factor (RF) was observed in 14 patients (23.3%). Anti-Ro (SSA) antibodies were detected in 11 patients (15.9%) and anti-La (SSB) in 6 patients (8.7%) in this study. Only 16 patients (23.2%) had true SS, according to the American-European Consensus Group on Classification Criteria for Sjögren's syndrome. The findings in the study corroborate data found in literature. Conclusion: This study confirms that Sicca symptoms are found in a large number of patients with SSc. Sjögren prevalence was observed in 23.2% of the SSc patients, including patients with limited and diffuse cutaneous subtype of disease. Key words: Sicca syndrome, Sjögren's syndrome, overlap, autoantibodies, systemic sclerosis

Introducción: Varias enfermedades autoinmunes pueden ir acompañadas de disfunción de las glándulas salivales, independientemente de la presencia o ausencia de asociación con el síndrome de Sjögren (SS). Un estudio reciente de Maeshima y sus colegas hallaron hiposecreción salival en el 58,3% de los pacientes con diversas enfermedades del tejido conectivo, particularmente la esclerosis sistémica (SSc). Objetivo: Determinar la prevalencia de los síntomas de SS y sicca en pacientes con SSc. Evaluar si la presencia de SS en pacientes con SSc provoca empeoramiento de la enfermedad. Métodos: 69 pacientes SSc periódicamente monitorizados en la clínica de reumatología en NHU/UFMS formaron parte del estudio. Todos los pacientes fueron interrogados acerca de síntomas sicca y características clínicas. Se evaluaron los niveles de FR, FAN, anti-Ro/La. Resultados y discusión: Se incluyeron 69 pacientes SSc en el estudio, con edad promedio de 51,2 años, 98,3% mujeres y 50% caucásicos. Los síntomas de Sicca estuvieron presentes en 48 pacientes (69,5%) con SSc; 43/69 pacientes (62,3%) con boca seca y 46/69 pacientes (66,7%) con ojo seco. Síntomas sicca se observaron en pacientes con forma limitada y difusa de la enfermedad. La positividad del anticuerpo antinuclear fue del 95% y el factor reumatoideo se observó en 14 pacientes (23,3%). Anticuerpos Anti-Ro (SSA) se detectaron en 11 pacientes (15,9%) y anti-La (SSB) en 6 pacientes (8,7%) en este estudio. Sólo 16 pacientes (23,2%) tenían verdaderas SS, según el Grupo de Consenso Americano-Europeo sobre los criterios de clasificación para el síndrome de Sjögren. Los hallazgos del estudio corroboran los datos encontrados en la literatura. Conclusión: Este estudio confirma que los síntomas sicca se encuentran en un gran número de pacientes con SSc. Se observó una prevalencia de Sjögren en el 23,2% de los pacientes con esclerodermia, incluyendo pacientes con subtipo cutáneo limitado y difuso

Scleroderma, Systemic , Sjogren's Syndrome
Rev. bras. reumatol ; 55(3): 229-239, May-Jun/2015. tab, graf
Article in Portuguese | LILACS | ID: lil-752089


Introdução: a esclerose sistêmica (ES) é uma enfermidade do tecido conjuntivo de caráter autoimune caracterizada pela tríade de injúria vascular, autoimunidade (celular e humoral) e fibrose tecidual. Os autoanticorpos não parecem ser simplesmente epifenômenos, mas sim estarem envolvidos na patogênese da doença. Acredita-se que os autoanticorpos específicos da ES são responsáveis tanto pela amplificação da resposta imune quanto por alvejar os tipos celulares que são relevantes na fisiopatologia da ES. Objetivos: correlacionar o perfil de autoanticorpos específicos (anti-SCL70, ACA, anti-POL3) com as manifestações clínicas e laboratoriais observadas em 46 pacientes com ES da região Centro-Oeste do Brasil. Métodos: pesquisou-se a ocorrência de autoanticorpos específicos em 46 pacientes com diagnóstico de ES e correlacionou-se o tipo de autoanticorpo com as manifestações clínicas e laboratoriais encontradas. Resultados: dentre todos os pacientes avaliados, encontrou-se predomínio feminino (97,8%), idade média de 50,21 anos, cor branca (50%), forma limitada da doença (47,8%), tempo de diagnóstico entre cinco e 10 anos (50%) e tempo de evolução da doença de 9,38 anos. De acordo com o autoanticorpo específico, 24 pacientes apresentavam ACA positivo (52,2%), 15 apresentavam positividade para anti-SCL70 (32,6%) e sete apresentavam anti-POL3 positivo (15,2%). O autoanticorpo anti-SCL70 se correlacionou com a forma difusa da doença, com maior gravidade e atividade da doença, com pior qualidade de vida medida pelo índice HAQ, com maior prevalência de fenômeno de Raynaud objetivo e microcicatrizes de polpas digitais. O ACA se correlacionou com a forma limitada da doença, com o início mais precoce da enfermidade, bem como com maior prevalência de telangiectasias nos pacientes. Já o anti-POL3 se correlacionou com a forma difusa da doença, com maior ocorrência de fenômeno de Raynaud subjetivo e de atrofia muscular. Para as demais variáveis relacionadas ...

Introduction: Systemic sclerosis (SSc) is a connective tissue disease of autoimmune nature characterized by the triad of vascular injury, autoimmunity (cellular and humoral) and tissue fibrosis. Autoantibodies do not seem to be simply epiphenomena, but are involved in disease pathogenesis. It is believed that the SSc-specific autoantibodies are responsible both for amplifying immune response and targeting cell types that are relevant in the pathophysiology of SSc. Objectives: To correlate the profile of the following specific autoantibodies: anti-centromere (ACA), anti-topoisomerase I (topo I) and anti-RNA polymerase III (RNAP III) with clinical and laboratory manifestations were observed in 46 patients with SSc in the Midwest region of Brazil. Methods: The occurrence of specific autoantibodies in 46 patients with SSc was investigated, correlating the type of autoantibody with clinical and laboratory manifestations found. Results: Among all patients evaluated, we found a predominance of females (97.8%), mean age 50.21 years old, Caucasian (50%), limited cutaneous SSc (47.8%), time of diagnosis between 5 and 10 years (50%), and disease duration of 9.38 years. According to the specific autoantibody profile, 24 patients were ACA-positive (52.2%), 15 were positive for anti-topo I (32.6%), and 7 showed positive anti-RNAP III (15.2%). The anti-topo I autoantibody correlated with diffuse scleroderma, with greater disease severity and activity, with worse quality of life measured by the SHAQ index, with a higher prevalence of objective Raynaud's phenomenon and digital pitting scars of fingertips. The ACA correlated with limited scleroderma, with earlier onset of disease, as well as higher prevalence of telangiectasias. The anti-RNAP III correlated with diffuse scleroderma, with a higher occurrence of subjective Raynaud's phenomenon and muscle atrophy. There was no association between the positivity for anti-topo I, ACA and anti-RNAP III antibodies ...

Humans , Male , Female , Middle Aged , Autoantibodies/blood , Scleroderma, Systemic/blood , Scleroderma, Systemic/immunology , Brazil , Cross-Sectional Studies , Prospective Studies
Rev. bras. reumatol ; 55(1): 48-54, Jan-Feb/2015. tab
Article in Portuguese | LILACS | ID: lil-744677


Objetivo Avaliar os resultados da aplicação do Índice de Atividade de Doença da Espondilite Anquilosante de Bath (BASDAI) numa série de pacientes brasileiros com EpA e estabelecer suas correlações com as variáveis específicas do grupo. Métodos Um protocolo comum de investigação foi prospectivamente aplicado em 1.492 pacientes brasileiros classificados como EpA pelos critérios do Grupo Europeu de Estudo das Espondiloartropatias (ESSG), acompanhados em 29 centros de referência em reumatologia no Brasil. Variáveis clínicas, demográficas e índices de doença foram colhidos. Os valores totais do BASDAI foram comparados com a presença das diferentes variáveis. Resultados O valor médio do BASDAI foi de 4,20 ± 2,38. Os escores médios do BASDAI foram mais elevados nos pacientes com forma clínica combinada, comparado às formas axiais e periféricas isoladas, nos pacientes do sexo feminino e nos sedentários. Com relação ao componente axial, valores mais altos do BASDAI estiveram significativamente associados à lombalgia inflamatória, à dor alternante em nádegas, à dor cervical e ao acometimento de coxofemorais. Houve associação estatística entre os valores do BASDAI e o comprometimento periférico, relacionado ao número de articulações inflamadas, tanto dos membros inferiores quanto dos membros superiores, e às entesites. A positividade do HLA-B27 e a presença de manifestações extra-articulares não estiveram correlacionadas com os valores médios do BASDAI. Valores mais baixos do BASDAI estiveram associados ao uso de agentes biológicos (p < 0,001). Conclusão Nesta série heterogênea de pacientes brasileiros com EpA, o BASDAI conseguiu demonstrar “atividade de doença” tanto nos pacientes com acometimento axial quanto naqueles com envolvimento periférico. .

Objective To analyze the results of the application of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in a large series of Brazilian patients with the diagnosis of SpA and establish its correlations with specific variables into the group. Methods A common protocol of investigation was prospectively applied to 1492 Brazilian patients classified as SpA according to the European Spondyoarthropathies Study Group (ESSG), attended at 29 referral centers of Rheumatology in Brazil. Clinical and demographic variables, and disease indices (BASDAI, Basfi, Basri, Mases, ASQol) were applied. The total values of BASDAI were compared to the presence of the different variables. Results The mean score of BASDAI was 4.20 ± 2.38. The mean scores of BASDAI were higher in patients with the combined (axial + peripheral + entheseal) (4.54 ± 2.38) clinical presentation, compared to the pure axial (3.78 ± 2.27) or pure peripheral (4.00 ± 2.38) clinical presentations (P < 0.001). BASDAI also presented higher scores associated with the female gender (P < 0.001) and patients who did not practice exercises (P < 0.001). Regarding the axial component, higher values of BASDAI were significantly associated with inflammatory low back pain (P < 0.049), alternating buttock pain (P < 0.001), cervical pain (P < 0.001) and hip involvement (P < 0.001). There was also statistical association between BASDAI scores and the peripheral involvement, related to the lower (P = 0.004) and upper limbs (P = 0.025). The presence of enthesitis was also associated to higher scores of BASDAI (P = 0.040). Positive HLA-B27 and the presence of cutaneous psoriasis, inflammatory bowel disease, uveitis and urethritis were not correlated with the mean scores of BASDAI. Lower scores of BASDAI were associated with the use of biologic agents (P < 0.001). Conclusion In this heterogeneous Brazilian series of SpA patients, BASDAI was able to demonstrate “disease ...

Humans , Male , Female , Spondylarthritis/diagnosis , Brazil , Prospective Studies , Registries , Severity of Illness Index , Spondylitis, Ankylosing/diagnosis
Rev. bras. reumatol ; 54(1): 33-37, Jan-Feb/2014. tab
Article in Portuguese | LILACS | ID: lil-704284


Introdução: Poucos estudos avaliaram o perfil do uso de drogas modificadoras de doença (DMD) em pacientes brasileiros com diagnóstico de espondiloartrite (EpA). Métodos: Um protocolo comum de investigação foi prospectivamente aplicado em 1505 pacientes classificados como EpA pelos critérios do Grupo Europeu de Estudo das Espondiloartrites (ESSG), acompanhados em 29 centros de referência em Reumatologia no Brasil. Variáveis clínicas e demográficas foram obtidas e avaliadas, analisando-se suas correlações com o uso das DMD metotrexato (MTX) e sulfasalazina (SSZ). Resultados: Pelo menos uma DMD foi utilizada por 73,6% dos pacientes, sendo MTX por 29,2% e SSZ por 21,7%, enquanto 22,7% utilizaram ambas as drogas. O uso do MTX foi significativamente associado ao acometimento periférico, e a SSZ foi associada ao comprometimento axial, sendo que as duas drogas foram mais utilizadas, isoladas ou combinadas, no comprometimento misto (p < 0,001). O uso de uma DMD esteve significativamente associado à etnia branca (MTX; p = 0,014), lombalgia inflamatória (SSZ; p = 0,002), dor em nádegas (SSZ; p = 0,030), cervicalgia (MTX; p = 0,042), artrite de membros inferiores (MTX; p < 0,001), artrite de membros superiores (MTX; p < 0,001), entesite (p = 0,007), dactilite (MTX; p < 0,001), doença inflamatória intestinal (SSZ; p < 0,001) e acometimento ungueal (MTX; p < 0,001). Conclusão: O uso de pelo menos uma DMD foi referido por mais de 70% dos pacientes numa grande coorte brasileira de pacientes com EpA, sendo o uso do MTX mais associado ao acometimento periférico e o uso da SSZ mais associado ao acometimento axial. .

Introduction: Few studies have evaluated the profile of use of disease modifying drugs (DMD) in Brazilian patients with spondyloarthritis (SpA). Methods: A common research protocol was applied prospectively in 1505 patients classified as SpA by criteria of the European Spondyloarthropathies Study Group (ESSG), followed at 29 referral centers in Rheumatology in Brazil. Demographic and clinical variables were obtained and evaluated, by analyzing their correlation with the use of DMDs methotrexate (MTX) and sulfasalazine (SSZ). Results: At least one DMD was used by 73.6 % of patients: MTX by 29.2 % and SSZ by 21.7%, while 22.7 % used both drugs. The use of MTX was significantly associated with peripheral involvement, and SSZ was associated with axial involvement, and the two drugs were more administered, separately or in combination, in the mixed involvement (p < 0.001). The use of a DMD was significantly associated with Caucasian ethnicity (MTX , p = 0.014), inflammatory back pain (SSZ, p = 0.002) , buttock pain (SSZ, p = 0.030), neck pain (MTX, p = 0.042), arthritis of the lower limbs (MTX, p < 0.001), arthritis of the upper limbs (MTX, p < 0.001), enthesitis (p = 0.007), dactylitis (MTX, p < 0.001), inflammatory bowel disease (SSZ, p < 0.001) and nail involvement (MTX, p < 0.001). Conclusion: The use of at least one DMD was reported by more than 70% of patients in a large cohort of Brazilian patients with SpA, with MTX use more associated with peripheral involvement and the use of SSZ more associated with axial involvement. .

Female , Humans , Male , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Methotrexate/therapeutic use , Registries , Spondylarthritis/drug therapy , Sulfasalazine/therapeutic use , Brazil , Prospective Studies
Rev. Soc. Bras. Med. Trop ; 46(3): 288-292, May-Jun/2013. tab, graf
Article in English | LILACS | ID: lil-679528


Introduction The progression of human papillomavirus (HPV) infection in the anogenital tract has been associated with the involvement of cells with regulatory properties. Evidence has shown that glucocorticoid-induced tumor necrosis factor receptor (GITR) is an important surface molecule for the characterization of these cells and proposes that GITR ligand may constitute a rational treatment for many cancer types. We aimed to detect the presence of GITR and CD25 in cervical stroma cells with and without pathological changes or HPV infection to better understand the immune response in the infected tissue microenvironment. Methods We subjected 49 paraffin-embedded cervical tissue samples to HPV DNA detection and histopathological analysis, and subsequently immunohistochemistry to detect GITR and CD25 in lymphocytes. Results We observed that 76.9% of all samples with high GITR expression were HPV-positive regardless of histopathological findings. High GITR expression (77.8%) was predominant in samples with ≥1,000 RLU/PCB. Of the HPV-positive samples negative for intraepithelial lesion and malignancy, 62.5% had high GITR expression. High GITR expression was observed in both carcinoma and high-grade squamous intraepithelial lesion (HSIL) samples (p = 0.16). CD25 was present in great quantities in all samples. Conclusions The predominance of high GITR expression in samples with high viral load that were classified as HSIL and carcinoma suggests that GITR+ cells can exhibit regulatory properties and may contribute to the progression of HPV-induced cervical neoplasia, emphasizing the importance of GITR as a potential target for immune therapy of cervical cancer and as a disease evolution biomarker. .

Adult , Female , Humans , Middle Aged , Cervical Intraepithelial Neoplasia/immunology , Glucocorticoid-Induced TNFR-Related Protein/analysis , /analysis , Papillomavirus Infections/immunology , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/virology , Cervical Intraepithelial Neoplasia/virology , Disease Progression , Immunohistochemistry , Papillomavirus Infections/complications , T-Lymphocytes, Regulatory/immunology , Biomarkers, Tumor/analysis , Uterine Cervical Dysplasia/immunology , Uterine Cervical Neoplasms/immunology
Rev. bras. reumatol ; 52(1): 49-54, jan.-fev. 2012. tab
Article in Portuguese | LILACS | ID: lil-611470


Estudos recentes sobre o torque teno vírus (TTV), gênero Anellovirus, permitiram construir a hipótese de que esse vírus pode ser um desencadeante ou tenha algum papel patogênico nas doenças reumáticas autoimunes. OBJETIVOS: Verificar a frequência da infecção pelo TTV em pacientes com lúpus eritematoso sistêmico (LES), e sua diversidade gênica, a existência de correlação entre a infecção pelo TTV e as manifestações clínicas do LES, sua evolução clínica e o perfil sorológico. PACIENTES E MÉTODOS: Foram obtidas 46 amostras de soro de pacientes com LES atendidos no Ambulatório de Reumatologia do Hospital Universitário de Campo Grande (NHU/FAMED/UFMS). Para os controles, utilizaram-se 46 amostras de soro de doadores de sangue. O DNA viral foi extraído das amostras utilizando o QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Alemanha), e amplificado utilizando a técnica de nested PCR. RESULTADOS: Foi encontrada positividade para o TTV em 17 (37 por cento) dos pacientes lúpicos, e em apenas sete (15,2 por cento) dos controles (teste z, P = 0,03). Não houve correlação entre a infecção pelo TTV, as manifestações clínicas, o perfil sorológico e a evolução clínica dos pacientes avaliados neste estudo. CONCLUSÃO: A presença do TTV nos pacientes com LES necessita ser mais bem compreendida a partir deste estudo inicial.

Recent studies on the torque teno virus (TTV), genus Anellovirus, have allowed formulating the hypothesis that TTV may trigger autoimmune rheumatic diseases or have some pathogenic role in them. OBJECTIVES: To determine the frequency of TTV infection in patients with systemic lupus erythematosus (SLE), the genetic diversity of TTV, the correlation between TTV infection and SLE clinical manifestations, and SLE clinical course and serological profile. PATIENTS AND METHODS:Serum samples were obtained from 46 SLE patients treated at the University-Affiliated Hospital of Campo Grande (NHU/FAMED/UFMS), Brazil. For controls, serum samples were obtained from 46 healthy volunteer blood donors. Viral DNA was extracted from samples using the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) and amplified using nested PCR. RESULTS: Positivity for TTV was found in 17 (37 percent) of SLE patients and in only seven (15.2 percent) of the controls (z test, P = 0.03). There was no correlation between TTV infection, SLE clinical manifestations, SLE clinical course, and the serological profile of the patients evaluated. CONCLUSION: Further studies on the presence of TTV in SLE patients are required.

Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , DNA Virus Infections/complications , DNA Virus Infections/epidemiology , Lupus Erythematosus, Systemic/complications , Torque teno virus/genetics , Brazil , DNA Virus Infections/blood , Genetic Variation , Lupus Erythematosus, Systemic/blood , Prevalence
Rev. Soc. Bras. Med. Trop ; 44(6): 674-677, Nov.-Dec. 2011. ilus, tab
Article in English | LILACS | ID: lil-611778


INTRODUCTION: Hepatic disorders caused by dengue infection may progress to severe manifestations, including mortality and morbidity. Cytokines are involved in it, such as the migration inhibitory factor of macrophages (MIF), tumor necrosis factor (TNF), natural killer cells (NK), B lymphocytes, and macrophages. METHODS: This study was carried out from January to April 2007 at a public hospital from the Federal University of Mato Grosso do Sul, Campo Grande, Brazil. Sixty-eight patients were studied concerning hepatic alterations, with 56 reported having classic dengue, 6 with hemorrhagic dengue grade I, and 6 with hemorrhagic dengue grade II. RESULTS: Among the 56 with classic dengue, 83.3 percent had aspartate aminotransferase (AST) alterations, and 69.6 percent had altered alanine aminotransferase (ALT). For those with hemorrhagic dengue grade I, 100 percent had AST alterations, and 83.3 percent had altered ALT. All the patients with hemorrhagic dengue grade II had AST and ALT alterations. AST variations reached 22.0 and 907.0, with an average value of 164.6. For ALT, we found variations between 25.0 and 867.0, with an average value of 166.07. There had been statistical significance between dengue clinical shapes and hepatic function markers. CONCLUSIONS: We conclude that the infection was predominant in adults, females, and in those with low income and education. The liver enzymes were of larger amount in hemorrhagic dengue, but there was weak statistical evidence of the clinical manifestations and transaminases. Major signs and clinical symptoms were fever, headache, myalgia, arthralgia, weakness, severe pain behind the eyes, and rashes.

INTRODUÇÃO: Afecções hepáticas causadas pela infecção da dengue podem evoluir para quadro grave, incluindo mortalidade e morbidade. O mecanismo de lesão do fígado está relacionado com a exacerbação da resposta imune. As citocinas estão envolvidas nele como fator inibidor da migração de macrófagos (MIF), fator de necrose tumoral (TNF), células natural killer (NK), B linfócitos e macrófagos. MÉTODOS: Este estudo foi realizado em um hospital público da Universidade Federal do Mato Grosso do Sul. As alterações hepáticas pelo dengue podem evoluir com quadros graves e potencialmente letais. Foram avaliados exames de 68 pacientes atendidos e confirmados com dengue, onde 56 foram classificados como dengue clássico, seis, como dengue hemorrágico grau I e seis como dengue hemorrágico grau II. RESULTADOS: Do dengue clássico, 83,3 por cento tiveram alterações de aspartato aminotransferase (AST) e 69,6 por cento alterações para alanino aminotransferase (ALT). No dengue hemorrágico grau I, AST elevou-se 100 por cento e para ALT 83,3 por cento. No dengue hemorrágico grau II observou-se 100 por cento de alterações tanto para AST, quanto para ALT. A variação de AST ficou entre 22,0 e 907,0 com média de 164,6. A alanino aminotransferase variou entre 25,0 e 867,0 com média de 166,07. Houve significância entre formas clínicas do dengue e marcadores de função hepática. CONCLUSÕES: Conclui-se que a infecção predominou em adultos do sexo feminino, de baixa renda e escolaridade. As enzimas hepáticas elevam-se mais no dengue hemorrágico, fraca evidência estatística entre as manifestações clínicas e as transaminases. Os mais prevalentes sinais/sintomas clínicos foram febre, cefaléia, mialgia, artralgia, fraqueza, dor retrorbitária e exantema.

Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Biomarkers/blood , Dengue/complications , Liver Diseases/virology , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Severe Dengue/blood , Severe Dengue/complications , Dengue/blood , Liver Diseases/blood , Severity of Illness Index , Socioeconomic Factors
Rev. bras. reumatol ; 50(4): 408-414, jul.-ago. 2010. tab
Article in Portuguese | LILACS | ID: lil-557962


INTRODUÇÃO/OBJETIVO: Avaliar a qualidade de vida (QV) de mulheres com lúpus eritematoso sistêmico (LES) e verificar a associação entre os domínios de QV medidos pelo instrumento World Health Organization Quality of Life Group (WHOQOL-100) da OMS e a atividade da doença. PACIENTES E MÉTODOS: Estudo seccional analítico com 95 pacientes com LES segundo critérios do Colégio Americano de Reumatologia (ACR), com idade entre 20 e 49 anos, atendidas no Núcleo Universitário da Universidade Federal de Mato Grosso do Sul, Campo Grande, MS. Os instrumentos utilizados para a coleta de dados foram: formulário para coleta de dados sociodemográficos e clínicos e o WHOQOL-100. Procedeu-se à avaliação da atividade de doença através do SLEDAI. Aplicaram-se testes estatísticos t de Student, análise de variância e correlação linear de Pearson. RESULTADOS: Grupo-caso: 79 mulheres com LES em atividade leve a moderada (SLEDAI = 1-10) e intensa (SLEDAI > 11). Grupo-controle: 16 mulheres com LES inativo (SLEDAI = 0). Todos os domínios de QV do WHOQOL-100 revelaram-se afetados, com diferenças significativas (P < 0,005) entre os grupos caso e controle, nos quais houve melhor percepção de QV no domínio espiritual e pior no ambiental. Ao se confrontarem os domínios de QV com a escolaridade, detectou-se diferença significativa (P < 0,05) nos domínios físico, psicológico, nível de independência e ambiental. A comparação entre QV e atividade da doença revelou significância (P < 0,005) em três domínios: físico, psicológico e ambiental. CONCLUSÃO: O LES em atividade intensa determina pior condição de QV do que o LES sem atividade. A avaliação de QV permite conhecer o impacto da doença e do tratamento de forma contextualizada, e pode tornar as intervenções mais apropriadas e abrangentes.

INTRODUCTION/OBJECTIVE: Evaluate the quality of life (QOL) of women with systemic lupus erythematosus (SLE) and the association between QOL domains, measured by the World Health Organization Quality of Life Group (WHOQOL-100) assessment instrument, and disease activity. PATIENTS AND METHODS: A cross-sectional analytic study involving 95 patients with SLE, according to the American College of Rheumatology (ACR) criteria, aged 20-49 years, attended at the University Center of Universidade Federal de Mato Grosso do Sul, Campo Grande, MS. We used the following instruments: demographic and clinical data collection form and WHOQOL-100 instrument. Evaluation of disease activity was performed by SLEDAI. On statistical analysis, we applied Student's t-test, ANOVA, and Pearson's correlation. RESULTS: Group-case: 79 female with mild to moderate SLE activity (SLEDAI = 1-10) and severe activity (SLEDAI > 11). Control group: 16 female with inactive SLE (SLEDAI = 0). All domains of WHOQOL-100 proved to be affected, with significant difference (P < 0.005) between the case and control groups in which there was a better perception of QOL in the domain Spirituality and worst perception of QOL in the domain Environment. When confronting QOL domains with education, we detected a significant difference (P < 0.05) in the Physical, Psychological, Level of independence, and Environment domains. The comparison between QOL and disease activity was significant (P < 0.005) in three domains: Physical, Psychological, and Environment. CONCLUSION: SLE with intense activity determines a worse QOL condition than inactive SLE. The assessment of QOL enables the knowledge of disease and treatment impact in a contextualized way, which can render more appropriate and more comprehensive interventions.

Adult , Female , Humans , Middle Aged , Young Adult , Lupus Erythematosus, Systemic , Quality of Life , Brazil , Cross-Sectional Studies , Lupus Erythematosus, Systemic/physiopathology
Rev. bras. reumatol ; 50(1): 90-95, jan.-fev. 2010. ilus
Article in Portuguese | LILACS | ID: lil-543760


Complicações do Sistema Nervoso Central (SNC) raramente são descritas em miopatias inflamatórias idiopáticas. Os autores relatam o caso de uma paciente de 48 anos com diagnóstico de polimiosite com autoanticorpo anti-Jo-1 positivo que, após cinco anos de evolução, apresentou extensa lesão desmielinizante do SNC associada à arterite linfocítica.

Central Nervous System (CNS) complications in idiopathic inflammatory myopathies are seldom reported. The authors describe the case of a 48-year old female with polymyositis and positive anti-Jo-1 autoantibody who, after five years of evolution, developed extensive CNS demyelinating injury associated with lymphocytic arteritis.

Humans , Female , Middle Aged , Autoantibodies , Myositis , Polymyositis , Vasculitis, Central Nervous System
Rev. bras. reumatol ; 49(6): 643-657, nov.-dez. 2009. tab
Article in English, Portuguese | LILACS | ID: lil-534779


OBJETIVO: Avaliar traços de personalidade e suas alterações em pacientes do sexo feminino com Lúpus Eritematoso Sistêmico (LES), procurando relacionar mudanças na atividade da doença com alterações nos traços de personalidade dessas pacientes. PACIENTES E MÉTODOS: Foram selecionadas 20 pacientes do Ambulatório de Reumatologia do Hospital Universitário da Universidade Federal de Mato Grosso do Sul (UFMS). Após a avaliação inicial, elas foram reavaliadas em três e em seis meses, em relação à presença de Transtornos Psiquiátricos (particularmente alterações da personalidade) e atividade do lúpus. Além das avaliações clínicas psiquiátricas e reumatológicas, as escalas utilizadas para avaliação das pacientes foram a Escala Fatorial de Ajustamento Emocional/Neuroticismo (EFN) e a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). RESULTADOS: Em todos os tempos analisados não houve relação significativa entre a pontuação na SLEDAI e o escore da EFN. Não foi encontrada, portanto, associação entre alterações da personalidade e atividade do lúpus. De acordo com a EFN, seis pacientes (30 por cento) apresentaram pontuação sugestiva de Transtornos de Personalidade, porém apenas duas (10 por cento) tiveram esse diagnóstico pela avaliação psiquiátrica. Também não foi encontrado um padrão típico de personalidade ou prevalência de um Transtorno de Personalidade específico na amostra; entretanto, houve uma prevalência importante de Depressão (65 por cento). CONCLUSÕES: Verificou-se na população estudada que as pacientes lúpicas podem apresentar os mais variados tipos de comportamento e sintomas psiquiátricos, não havendo nelas um padrão típico de personalidade. Não foi encontrada uma relação significativa entre as alterações de personalidade e atividade da doença.

OBJECTIVE: The objective of the present study was to evaluate personality traits and associated changes in female patients with Systemic Lupus Erythematosus (SLE), linking variations in disease activity with alterations in personality traits. PATIENTS AND METHODS: Twenty patients from the Rheumatology Outpatient Clinic at the University Hospital of Universidade Federal de Mato Grosso do Sul (UFMS) participated in this study. Patients were re-evaluated three and six months after the initial evaluation for the presence of Psychiatric Disorders (especially personality changes) and lupus activity. The Adjustment/Neuroticism Factorial Scale (AFS) and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), along with clinical psychiatric and rheumatologic assessment, were used to evaluate patients. RESULTS: No significant correlation between SLEDAI and AFS scores was observed. According to the AFS, the scores of six patients (30 percent) were suggestive of Personality Disorders, but psychiatric evaluation confirmed this diagnosis in only two (10 percent) patients. A typical personality pattern or prevalence of a specific Personality Disorder was not observed; however, an important prevalence of Depression (65 percent) was observed. CONCLUSIONS: Our findings showed that patients with lupus can develop different types of behavior and psychiatric symptoms without a typical personality trait. No significant correlation between personality changes and disease activity was observed.

Humans , Female , Adolescent , Adult , Middle Aged , Autoimmune Diseases , Depression , Lupus Erythematosus, Systemic , Mental Disorders , Personality Disorders , Psychiatric Status Rating Scales
Rev. bras. reumatol ; 49(5): 492-505, set.-out. 2009. tab
Article in English, Portuguese | LILACS | ID: lil-531518


INTRODUÇÃO: A doença de Lyme (DL) é uma doença de picada de carrapato, causado pela espiroqueta Borrelia burgdorferi sensu lato, transmitida por carrapatos do complexo Ixodes ricinus, que promove múltiplas manifestações clínicas sistêmicas. No Brasil, uma síndrome diferente é descrita e mimetiza sintomas de DL, mas também se manifesta com alta frequência de episódios recorrentes e manifestações alérgicas e imunológicas. É transmitida pelo carrapato Amblyomma cajennense e o agente etiológico é uma espiroqueta não cultivável de forma atípica. Devido a essas particularidades, esta zoonose emergente tem sido denominada síndrome brasileira semelhante à doença de Lyme ou síndrome de Baggio-Yoshinari (SBY). OBJETIVO: Descrever o espectro da manifestação neurológica da SBY. PACIENTES: Foram analisados 30 pacientes com SBY e sintomas neurológicos. RESULTADOS: A média de idade dos pacientes foi de 34,2 ± 13,3 anos (6 a 63 anos); 20 eram mulheres e 10 homens. Um alto número de episódios recorrentes (73,6 por cento) e distúrbios psiquiátricos e psicossociais graves (20 por cento) foram características típicas. Eritema migrans similar ao visto em hemisfério norte foi identificado em 43,3 por cento dos pacientes no início da doença. A recorrência das lesões cutâneas diminuiu com a progressão da doença. Sintomas articulares (artrite) aconteceram em aproximadamente metade dos pacientes com SBY no início e durante o episódio de recidiva. CONCLUSÕES: A SBY é considerada uma nova doença transmitida por carrapato no Brasil que difere da clássica DL observada no hemisfério norte. A SBY reproduz sintomas neurológicos observados na DL, exceto pela presença adicional de recorrência de episódios e uma tendência de causar manifestações neurológicas crônicas e articulares.

INTRODUCTION: Lyme disease (LD) is a tick-borne disease, caused by Borrelia burgdorferi sensu lato spirochetes, transmitted by Ixodes ricinus complex ticks, which leads to multiple systemic clinical manifestations. In Brazil, a different syndrome is described that mimics LD symptoms, but that also manifests high frequencies of recurrent episodes and immune-allergic manifestations. It is transmitted by the Amblyomma cajennense tick and the etiological agent is an uncultivable spirochete with atypical morphology. Due to its particularities, this emerging zoonosis has been called Brazilian LD-like syndrome or Baggio-Yoshinari Syndrome (BYS). OBJECTIVE: To describe the neurological spectrum of BYS. PATIENTS: Thirty patients with neurological symptoms of BYS were analyzed. RESULTS: Mean age of patients was 34.2 ± 13.3 years old (6 to 63 years); 20 were females and 10 males. A high number of recurrent episodes (73.6 percent) and severe psychiatric or psycho-social disturbances (20 percent) were distinguishing features. Erythema migrans similar to those seen in the Northern hemisphere was identified in 43.3 percent of patients at disease onset. The recurrence of skin lesions diminished as the disease progressed. Articular symptoms (arthritis) happened in nearly half of patients at BYS onset and during relapsing episodes. CONCLUSIONS: The BYS is considered a new tick borne disease in Brazil that differs from classical LD observed in the Northern hemisphere. BYS replicates most of the neurological symptoms observed in LD, except for the additional presence of relapsing episodes and the tendency to cause chronic neurological and articular manifestations.

Female , Child , Adolescent , Adult , Middle Aged , Borrelia burgdorferi , Borrelia burgdorferi/pathogenicity , Enzyme-Linked Immunosorbent Assay , Lyme Disease , Lyme Neuroborreliosis , Serology , Tick Infestations , Tick-Borne Diseases , Zoonoses